The Electronic Clinical Dementia Rating (eCDR): A Promising Tool for Dementia Screening

By Staff Writer

September 25, 2023

The Electronic Clinical Dementia Rating (eCDR) is a digital tool showing potential in dementia screening and staging, according to a recent cross-sectional study. The eCDR, which can be self-administered remotely and scored automatically, was compared to the Clinical Dementia Rating (CDR), a widely used instrument for detecting and staging dementia due to Alzheimer disease.

Recent study from the USA


The study involved 288 participants, aged 55 years and above, from three Alzheimer Disease Research Centers and the Brain Health Registry. Participants completed both the CDR and eCDR, with the latter being completed remotely and unsupervised.

The findings revealed that the eCDR showed high concordance with the CDR at item, box, and global levels. The concordance ranged from 80% for memory to 99% for personal care. The global score concordance rate was 81%. The study also found that eCDR scores correlated with CDR-SB scores with moderate to high accuracy.

These results suggest that the eCDR is a valid tool for screening and assessing cognitive and functional decline related to Alzheimer disease in older adults. The study emphasises the need for further validation and optimization of eCDR content and scoring in diverse populations and remote settings.

How does this work?

The eCDR works by allowing participants to complete the dementia screening and staging process remotely, using their own device. It is designed to be user-friendly and can be self-administered without supervision. Once the participant completes the eCDR, the tool automatically scores the results. This digital tool is structured similarly to the CDR, rating cognitive and functional impairment across multiple domains. However, unlike the CDR, the eCDR does not rely on clinical judgement to assign scores, instead using an automated scoring algorithm. This feature, along with its remote administration capability, makes the eCDR a potentially more efficient and accessible tool for dementia screening and staging. 


This could lessen the burden of in-clinic research visits by using remote administration with automated scoring could revolutionise dementia screening and assessment, facilitating clinical research, clinical trials, and healthcare.



Reference url

Recent Posts

Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Disease

By Staff Writer

August 15, 2025

Sanofi's rilzabrutinib has received orphan drug designation from the European Medicines Agency for treating IgG4-related disease (IgG4-RD). This reversible covalent Bruton's tyrosine kinase (BTK) inhibitor earned the designation based on promising Phase 2 study results. The findings, presented at...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing

By João L. Carapinha

August 13, 2025

What are the most expensive drugs 2025, and how do they shape patient access, healthcare spending, and industry innovation in the US? As 2026 approaches, the most expensive drugs 2025 are led by advanced gene therapies and rare disease biologics, with several treatments carrying annual price tags...
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Economic Impact
A newly published Pfizer press release presents clinical trial results indicating that the combination therapy PADCEV™ (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) significantly improves overall survival in patients with previously untreated locally advanced or metastatic urothelial c...